IBA and Bayer Schering Pharma Sign Clinical Trial Supply Agreement for Alzheimer’s Disease Tracer
Under the terms of the agreement, IBA will manufacture and supply Bayer and their trial partners with doses of the compound FLORBETABEN for clinical trials. IBA will develop a large-scale manufacturing process on Synthera®, its proprietary, multi-purpose automated synthesizer, and upgrade its positron emission tomography (PET) manufacturing network in order to ensure availability of the compound for the clinical trials.
Under the terms of the agreement IBA will receive several million Euros (single-digit) of milestone payments and fees depending on the amount of required doses for the clinical trials.
FLORBETABEN is a PET tracer in-licensed by Bayer, undergoing clinical development for potential use in diagnostic imaging of beta-amyloid deposits in the brain, a hallmark of Alzheimer’s Disease.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.